Login to Your Account



Other News To Note


Wednesday, June 6, 2012
• ERYtech Pharma, of Lyon, France, received more than $8.65 million from OSEO's Strategic Industrial Innovation program to lead the eight-year TEDAC project, which is focused on developing enzymes targeting chemo- and radio-resistant cancers, as well as tools to identify responders and enable personalized treatment.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription